This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
6 Stocks in Focus on Hiring Spree Despite Market Turmoil
by Nalak Das
Several retail stores, including supermarkets, grocery chains, medical and pharmacy stores, take-away restaurants and e-commerce companies are hiring people.
The Zacks Analyst Blog Highlights: Bristol-Myers Squibb, BHP, CVS Health, T-Mobile US and Anthem
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Bristol-Myers Squibb, BHP, CVS Health, T-Mobile US and Anthem
Top Research Reports for Bristol-Myers, BHP & CVS
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Bristol-Myers Squibb (BMY), BHP Group (BHP) and CVS Health (CVS).
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income - March 20, 2020
by Zacks Equity Research
The traditional approaches to retirement planning are longer covering all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
3 High-Yield REITs for Income Investors to Buy to Fight Coronavirus Volatility
by Benjamin Rains
Now, let's dive into three high-yield REITs that investors might want to buy to help add income amid the coronavirus market downturn...
Retirees Should Know These 3 Facts About Required Minimum Distributions - March 19, 2020
by Zacks Equity Research
Like the majority of investors, you're most likely working on a retirement portfolio that will provide a large enough nest egg to give you a comfortable retirement. Make sure you know all about what financial planners call the accumulation and distribution phases of retirement planning.
CVS Health (CVS) Stock Moves -1.41%: What You Should Know
by Zacks Equity Research
CVS Health (CVS) closed at $57.18 in the latest trading session, marking a -1.41% move from the prior day.
Teladoc Witnesses Higher Visits Due to Coronavirus Outbreak
by Zacks Equity Research
Teladoc's (TDOC) teleheath services are witnessing increase in demand due to coronavirus outbreak.
CVS Health (CVS) Down 24.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
CVS Health (CVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks - March 13, 2020
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
CVS Health's Schnuck Pharmacy Buyout to Widen Specialty Arm
by Zacks Equity Research
Given the growing prospects of specialty pharmacy, CVS Health (CVS) is prioritizing expansion of this business.
CVS Health's Latest Alliances to Fortify Kidney-Care Business
by Zacks Equity Research
With a growing incidence of chronic kidney diseases and end-stage renal failure in the United States, CVS Health's (CVS) new partnerships seem to be strategic.
Can Telemedicine be a Market Savior on Rising Corona Scare?
by Urmimala Biswas
Here are four telemedicine stocks which have robust prospects to become attractive picks on the COVID-19 economic doldrums.
3 Top Dividend Stocks to Maximize Your Retirement Income - March 03, 2020
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
3 Top Dividend Stocks to Maximize Your Retirement Income - February 26, 2020
by Zacks Equity Research
The traditional approaches to retirement planning are longer covering all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
Zacks Value Trader Highlights: AbbVie, Allergan, Occidental, Chevron and CVS
by Zacks Equity Research
Zacks Value Trader Highlights: AbbVie, Allergan, Occidental, Chevron and CVS
One of Your Stock Investments is Being Acquired: Now What?
by Tracey Ryniec
One of your companies gets a buyout offer and the shares soar. There might be different strategies for traders and investors on what to do next.
What's in Store for SmileDirectClub's (SDC) Q4 Earnings?
by Zacks Equity Research
SmileDirectClub (SDC) is likely to have gained from a strong international presence in Q4.
Top Stock Analyst Reports for Apple, American Express & Starbucks
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), American Express (AXP) and Starbucks (SBUX).
Know These 3 Facts to Avoid Paying Half Your Retirement Income to the IRS - February 13, 2020
by Zacks Equity Research
Like the majority of investors, you're most likely working on a retirement portfolio that will provide a large enough nest egg to give you a comfortable retirement. Make sure you know all about what financial planners call the accumulation and distribution phases of retirement planning.
The Federal Budget in Focus
by Zacks Equity Research
The Federal Budget in Focus
CVS Health (CVS) Q4 Earnings Top Estimates, Margins Improve
by Zacks Equity Research
CVS Health (CVS) registers strong growth in Pharmacy Services, benefiting from the upside in specialty services.
Shopify, CVS Outperform in Q4, Plus COVID-19 Update
by Mark Vickery
Shopify (SHOP) impressed investors with a big beat on both top and bottom lines: 43 cents per share versus 23 cents expected, on $505.2 million which easily surpassed the Zacks consensus $482.3 million.
Can Pharmacy Services Growth Aid CVS Health (CVS) Q4 Earnings?
by Zacks Equity Research
Expanded claims volume and better purchasing economics are expected to have aided CVS Health's (CVS) top line in Q4.
CVS Health (CVS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
CVS Health (CVS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.